

CLAIMS

- 10  
15  
20
- 5
1. An orally, parenterally, rectally or transdermally administrable pharmaceutical composition for treating cardiovascular, thromboembolic, atherosclerotic, hyperlipidemic disorders and obesity and for decreasing appetite, comprising L-carnitine or an alkanoyl L-carnitine wherein the alkanoyl group is a straight or branched alkanoyl having 2-8, preferably 2-6, carbon atoms or a pharmacologically acceptable salt thereof, and hydroxycitric acid or pantothenic acid or derivative thereof as active ingredients, and a pharmacologically acceptable excipient.
  2. The composition of claim 1, wherein the alkanoyl group is selected from acetyl, propionyl, butyryl, valeryl and isovaleryl.
  3. The composition of claims 1 or 2, wherein the hydroxycitric acid derivative is a salt or ester thereof, a natural product or extract thereof containing same.
  4. The composition of claims 1 or 2, wherein the pantothenic acid derivative is selected from the group comprising 4'-phosphopantothenate, 4'-phosphopantothenylcysteine, 4'-phosphopantotheine, pantotheine and pantethine.
- 1000000 4282/50

9. The composition of anyone of the preceding claims in a solid, semisolid, liquid, semiliquid, powder, granular or liposomic form, as tablets, capsules, granulates, powders and vials suitable for oral, parenteral, rectal or topic administration.

10 15

10. Co-ordinated use of L-carnitine or alkanoyl L-carnitine wherein the alkanoyl group has 2-8, preferably 2-6, carbon atoms, or pharmacologically acceptable salt thereof, and hydroxycitric acid or pantothenic acid or derivative thereof for treating cardiovascular, thromboembolic, atherosclerotic, hyperlipidaemic disorders and obesity, and for controlling and decreasing the appetite.

5

add A5

Add  
B4

T00000-408000